PDX Live™: Efficacy Studies on Demand

Highly characterized, clinically relevant models.
Fast study start-up and optimized study designs.
Time to data measured in weeks, not months.

REQUEST A QUOTE

Select a PDX Live™ Model


Type Model ID Tumor Markers

Bladder

TM00015 PIK3CA H1047R
TM00020 TP53 E336*; KDR Q472H; PTEN T321fs

Breast

TM00089 TNBC ER-/PR-/HER2-; BRCA1 V757fs
TM00096 TNBC ER-/PR-/HER2-
TM00098 TNBC ER-/PR-/HER2-
TM00386 ER+/PR+/HER2-

Colon

TM00170 BRAF V600E/PIK3CA G1049R

Lung

TM00302 KRAS G12D/KDR Q472H/TP53 R158L
TM00199 EGFR L858R
TM00206 ELM4-ALK fusion
Ovary TM00335 CA125 & MUC16 mRNA elevated
TM00916 ER+/PR+

Prostate

TM00298
TP53 R273C/PTEN R233*/PTEN L265fs, AR+

Skin

TM00702

TM01149 POLB P242R, NF1 R1362

† Cohorts from these PDX models have slower growth rates and will take longer to expand and run on study.

Choose a Study

Study Type Arms Vehicle SOC Drug A Drug B Combination
Drug A+B
1. Pilot efficacy study
3 1 1 1 0 0
2. Dose response 5 1 1 3 0 0
3. Drug combination 4 1 0 1 1 1
4. Tolerability 3 1 0 2 0 0

Study types 1-3 include the following:

  • 8 mice per arm (NSG™)
  • IV or IP dosing – (Oral dosing includes an additional charge)
  • Maximum of 28 day study duration
  • Twice weekly tumor caliper measurements and body weight
  • Simple necropsy with tumor collection and up to 3 tissues (or blood)
  • Analytical Study Report

Tolerability studies include the following:

  • 5 mice per arm
  • IV or IP dosing – no limit on frequency (Oral dosing includes an additional charge)
  • Cage observation – 14 days
  • Study report

Start Your Efficacy Study & Monitor Data Live

We provide you data in weeks with study-ready clinically relevant patient-derived xenografts in the most robust mouse models. 

Questions?

Contact Technical Support
micetech@jax.org
1.800.422.6423 (US)
1.207.288.5845 (International)

Example studies using PDX Live™ tumors

Pilot Combination Study Using a PDX Live™ Colon Adenocarcinoma

pdx_live_graph

Figure 1. Mice bearing passage 3 colon adenocarcinoma PDX tumor (TM00170) were treated with vehicle control: D5W (dark grey), 20mg/ kg 5-Fu (light blue), 10mg/kg Oxaliplatin (orange) and 5-Fu + Oxaliplatin (dark blue) once per week for 3 weeks. Vehicle and 5-Fu were administrated intravenously and Oxaliplatin was dosed intraperitoneally. The readout for compound efficacy–alone or in combination-was assessed by taking tumor caliper measurements and body weight twice weekly. Ten NSG™ mice were used per arm. 

Pilot Combination Study Using a PDX Live™ Invasive Ductal Carcinoma 

Figure 2. Mice bearing passage 4 TM00089 PDX tumor were treated with vehicle control (D5W), Cisplatin (2mg/kg), Cyclophosphamide (40mg/kg) and Doxorubicin (2mg/kg) intravenously, once per week for 3 weeks; Docetaxel (15mg/kg) was dosed once per week only for 2 weeks intravenously.

3A.  3B.  3C. 

Figure 3. A) Patient tumor for PDX model TM00089 (aka, BR0620); PR marker (negative). B) P0 tumor #037 for PDX model TM00089 (aka, BR0620F); estradiol supplemented; PR marker. C) P1 tumor for PDX model TM00089 (aka, BR0620F); estradiol supplemented; PR marker (negative)

Pilot Combination Study Using a PDX Live™ Lung Adenocarcinoma

Figure 4. Mice bearing TM00199 PDX samples at passage 3 were used to create five treatment groups of twelve mice each: vehicle control (0.5 % carboxymethylcellulose); erlotinib (50 mg/kg); afatinib (20 mg/kg); cetuximab (10 mg/kg); and afatinib plus cetuximab (20 mg/kg and 10 mg/kg, respectively). Vehicle, erlotinib, and afatinib were IP dosed daily for 21 days. Cetuximab was dosed intravenously three times weekly, for three weeks. Mice were monitored for tumor volume.

5A.  5B. 

Figure 5. A) P1 tumor #940_001 for PDX model TM00199 (aka, LG0703F). B) P1 tumor #940_006 for PDX model TM00199 (aka, LG0703F).